Cases & Deals

  • Home
  • Practices
  • Boehringer Ingelheim defends antitrust litigation involving Mirapex® patents

Share

Boehringer Ingelheim defends antitrust litigation involving Mirapex® patents

July 2009

Client(s) Boehringer Ingelheim GmbH

Jones Day represented Boehringer Ingelheim GmbH as antitrust defense counsel in litigation brought by the generic drug manufacturer Mylan claiming that Boehringer Ingelheim wrongfully enforced patents against Mylan for its drug Mirapex® to exclude generic competition from the market in violation of Sections 1 and 2 of the Sherman Act. Additional follow on class actions were brought against Boehringer Ingelheim by direct and indirect purchasers of Mirapex® asserting substantially similar antitrust claims. All plaintiffs voluntarily dismissed their complaints.

Mylan Inc. et al. v. Boehringer Ingelheim International GmbH, et al., No. 09-990 (W.D. Pa., filed July 2009)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.